-
2024-520444-42-00
5
2026-04-15
Overweight or obesity, and knee osteoarthritis
-
2024-520445-23-00
5
2026-04-15
Overweight or obesity, and knee osteoarthritis
-
2025-523079-44-00
5
2026-04-15
Turner Syndrome (TS)
-
2025-523553-34-00
1
2026-04-15
Advanced and Metastatic Solid tumors
-
2025-524542-10-00
4
2026-04-14
Endometrial cancer
-
2025-523085-24-00
5
2026-04-13
Biliary Tract Cancer
-
2023-509220-17-00
7
2026-04-10
Metastatic solid tumors
-
2024-512515-45-01
1
2026-04-10
Non-Small Cell Lung Cancer
-
2025-522403-17-00
5
2026-04-10
Nummular Dermatitis
-
2025-523658-15-00
5
2026-04-10
Obesity
-
2025-520972-24-00
5
2026-04-08
Chronic Obstructive Pulmonary Disease (COPD)
-
2025-523263-37-00
10
2026-04-08
Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal
-
2025-523931-21-00
1
2026-04-07
Advanced Malignant Solid Tumors
-
2024-520101-39-00
5
2026-04-01
TROP2 NMR-positive advanced or metastatic non-squamous non-small cell
-
2025-523499-22-00
5
2026-04-01
Hereditary Angioedema (HAE)
-
2025-524446-10-00
1
2026-04-01
Solid Malignancies
-
2024-517490-24-00
4
2026-03-31
Small Cell Lung Cancer
-
2025-521859-23-00
9
2026-03-31
PSMA-positive mCRPC with prior exposure to at least one prior ARPI
-
2025-522338-30-00
4
2026-03-31
Ulcerative Colitis
-
2025-522509-39-00
4
2026-03-30
Patients with myelofibrosis and platelets counts between 50 - 120 x 10
-
2025-523224-45-00
10
2026-03-30
Untreated, Unresectable or Metastatic Colorectal Cancer
-
2025-521459-22-00
4
2026-03-27
Patients with resectable hepatocellular carcinoma (amenable R0 resecti
-
2025-522544-40-00
5
2026-03-27
Hereditary transthyretin-mediated amyloidosis with polyneuropathy
-
2025-521286-27-00
10
2026-03-26
Immune-mediated thrombocytopenia, Autoimmune thrombocytopenia, Autoimm